Literature DB >> 34235599

Frailty is associated with poor prognosis after resection for pancreatic cancer.

Kosuke Mima1, Hiromitsu Hayashi1, Shigeki Nakagawa1, Takashi Matsumoto1, Shotaro Kinoshita1, Kazuki Matsumura1, Fumimasa Kitamura1, Norio Uemura1, Yosuke Nakao1, Rumi Itoyama1, Takayoshi Kaida1, Katsunori Imai1, Yo-Ichi Yamashita1, Hideo Baba2.   

Abstract

BACKGROUND: With population aging, the number of frail patients with pancreatic cancer has increased. The Clinical Frailty Scale (CFS) is a simple and validated tool to assess frailty, and higher scores predict worse clinical outcomes after cardiovascular surgery. In this retrospective study, we aimed to examine the association of preoperative frailty with prognosis after resection for pancreatic cancer.
METHODS: We retrospectively analyzed data from 142 consecutive patients undergoing resection for pancreatic cancer between April 2010 and December 2018. We used the CFS: 1 (very fit) to 9 (terminally ill) to assess frailty and examined associations of the CFS scores with recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS). Multivariable Cox proportional hazards models were used to calculate hazard ratios (HRs), controlling for potential confounders.
RESULTS: Of the 142 patients, 113 (80%) had CFS scores of ≤ 3, 13 (9.2%) scores of 4, and 16 (11%) scores of ≥ 5. Scores of ≥ 5 on the CFS were associated with worse CSS (univariable HR: 2.62, 95% confidence interval [CI]: 1.19-5.18, P = 0.019; multivariable HR: 2.49, 95% CI 1.05-5.34, P = 0.039) and OS (univariable HR: 2.42, 95% CI 1.19-4.46, P = 0.016; multivariable HR: 2.25, 95% CI 1.05-4.43, P = 0.038). The association between CFS scores and RFS was not significant in multivariable analysis (univariable HR: 2.11, 95% CI 1.08-3.79, P = 0.030; multivariable HR: 1.47, 95% CI 0.71-2.83, P = 0.29).
CONCLUSION: Higher scores on the CFS are associated with worse CSS and OS after resection for pancreatic cancer. Preoperative measurement of frailty may improve risk assessment among patients with pancreatic cancer.

Entities:  

Keywords:  Geriatrics; Morbidity; Oncology; Pre-habilitation; Rehabilitation

Year:  2021        PMID: 34235599     DOI: 10.1007/s10147-021-01983-z

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  46 in total

1.  A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study.

Authors:  Taiga Otsuka; Tsuyoshi Shirakawa; Mototsugu Shimokawa; Futa Koga; Yasunori Kawaguchi; Yujiro Ueda; Junichi Nakazawa; Azusa Komori; Satoshi Otsu; Shiho Arima; Masaru Fukahori; Yoshinobu Okabe; Akitaka Makiyama; Hiroki Taguchi; Takuya Honda; Taro Shibuki; Kenta Nio; Yasushi Ide; Toshihiko Mizuta; Kenji Mitsugi; Norio Ureshino
Journal:  Int J Clin Oncol       Date:  2021-01-23       Impact factor: 3.402

2.  Survival benefit of adjuvant chemotherapy in elderly patients with colon cancer: a systematic review and meta-analysis.

Authors:  Nobuaki Hoshino; Ryuhei Aoyama; Koya Hida
Journal:  Int J Clin Oncol       Date:  2021-01-09       Impact factor: 3.402

3.  Association between the baseline frailty and quality of life in patients with prostate cancer (FRAQ-PC study).

Authors:  Tomoko Hamaya; Shingo Hatakeyama; Masaki Momota; Takuma Narita; Hiromichi Iwamura; Yuta Kojima; Itsuto Hamano; Naoki Fujita; Teppei Okamoto; Kyo Togashi; Tohru Yoneyama; Hayato Yamamoto; Takahiro Yoneyama; Yasuhiro Hashimoto; Chikara Ohyama
Journal:  Int J Clin Oncol       Date:  2020-10-16       Impact factor: 3.402

Review 4.  Aging, cancer, and antitumor immunity.

Authors:  Hideki Ikeda; Yosuke Togashi
Journal:  Int J Clin Oncol       Date:  2021-03-30       Impact factor: 3.402

5.  Risk factors for gemcitabine plus nab-paclitaxel-induced interstitial lung disease in pancreatic cancer patients.

Authors:  Tsuyoshi Takeda; Takashi Sasaki; Koshiro Fukuda; Takafumi Mie; Takaaki Furukawa; Yuto Yamada; Akiyoshi Kasuga; Masato Matsuyama; Masato Ozaka; Naoki Sasahira
Journal:  Int J Clin Oncol       Date:  2020-11-11       Impact factor: 3.402

Review 6.  From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer.

Authors:  Christopher Nevala-Plagemann; Manuel Hidalgo; Ignacio Garrido-Laguna
Journal:  Nat Rev Clin Oncol       Date:  2019-11-08       Impact factor: 66.675

Review 7.  History of pancreatic surgery in Japan: Respect to the Japanese pioneers of pancreatic surgery.

Authors:  Hiroki Yamaue
Journal:  Ann Gastroenterol Surg       Date:  2020-03-04

Review 8.  Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma.

Authors:  Keinosuke Ishido; Kenichi Hakamada; Norihisa Kimura; Takuya Miura; Taiichi Wakiya
Journal:  Ann Gastroenterol Surg       Date:  2020-08-09

Review 9.  Optimizing the outcomes of pancreatic cancer surgery.

Authors:  Oliver Strobel; John Neoptolemos; Dirk Jäger; Markus W Büchler
Journal:  Nat Rev Clin Oncol       Date:  2019-01       Impact factor: 66.675

10.  Prognostic value of the Memorial Sloan Kettering Prognostic Score in metastatic pancreatic adenocarcinoma.

Authors:  Justin M Lebenthal; Junting Zheng; Paul A Glare; Eileen M O'Reilly; Andrew C Yang; Andrew S Epstein
Journal:  Cancer       Date:  2021-01-20       Impact factor: 6.860

View more
  2 in total

1.  The Prevalence and the Impact of Frailty in Hepato-Biliary Pancreatic Cancers: A Systematic Review and Meta-Analysis.

Authors:  Klara Komici; Micaela Cappuccio; Andrea Scacchi; Roberto Vaschetti; Giuseppe Delli Carpini; Vito Picerno; Pasquale Avella; Maria Chiara Brunese; Giuseppe Rengo; Germano Guerra; Leonardo Bencivenga
Journal:  J Clin Med       Date:  2022-02-20       Impact factor: 4.241

Review 2.  Treatment of Older Adult Patients with Glioblastoma: Moving towards the Inclusion of a Comprehensive Geriatric Assessment for Guiding Management.

Authors:  Manik Chahal; Brian Thiessen; Caroline Mariano
Journal:  Curr Oncol       Date:  2022-01-14       Impact factor: 3.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.